A January 2021 appraisal of REMAP-CAP’s early tocilizumab and sarilumab findings in critically ill patients with COVID-19. Dan Horner examines organ support and survival outcomes, strict eligibility criteria and the uncertainties that remained as the results moved rapidly into policy and public discussion.